The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 20, 2020

Filed:

Aug. 25, 2016
Applicant:

Conopco, Inc., Englewood Cliffs, NJ (US);

Inventors:

Mark Ian Fowler, Huntingdon, GB;

Huijun Wang, Shanghai, CN;

Assignee:

Conopco, Inc., Englewood Cliffs, NJ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/7048 (2006.01); A23L 33/105 (2016.01); A61K 9/00 (2006.01); A61K 31/352 (2006.01); A61K 31/357 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7048 (2013.01); A23L 33/105 (2016.08); A61K 9/0053 (2013.01); A61K 31/352 (2013.01); A61K 31/357 (2013.01); A23V 2002/00 (2013.01);
Abstract

Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. According to Node et al. (Cardiovascular diabetology, 8, 23 (2009)), repeated high post-prandial plasma glucose 'spikes' are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or 'blunting' of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak. Thus in a first aspect of the invention, an edible composition provided in the form of a single serving of one or more unit dosages comprising a combination of 2 to 200 mg of at least one homoisoflavonoid and 20 to 2000 mg of at least one flavonoid monoglucoside, and salts thereof.


Find Patent Forward Citations

Loading…